| melanoma
Tafinlar + Mekinist vs Zelboraf - Vemurafenib tablet, Film Coated
Side-by-side clinical, coverage, and cost comparison for melanoma.Deep comparison between: Tafinlar vs Drug B with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsDrug B has a higher rate of injection site reactions vs Tafinlar based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Drug B but not Tafinlar, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Tafinlar
Drug B
At A Glance
Oral
Twice daily
BRAF kinase inhibitor
—
Indications
- melanoma
- Non-Small Cell Lung Carcinoma
- Anaplastic thyroid carcinoma
- Low grade glioma
- Solid Neoplasm
—
Dosing
Melanoma 150 mg orally twice daily as single agent or in combination with trametinib 2 mg once daily, oral route.
Non-Small Cell Lung Carcinoma 150 mg orally twice daily in combination with trametinib 2 mg once daily, oral route.
Anaplastic thyroid carcinoma 150 mg orally twice daily in combination with trametinib 2 mg once daily, oral route.
Low grade glioma Weight-based dosing in pediatric patients (20-150 mg twice daily) in combination with trametinib, oral route.
Solid Neoplasm 150 mg orally twice daily in combination with trametinib 2 mg once daily in adults; weight-based dosing in pediatric patients >= 1 year, oral route.
—
Contraindications
—
—
Adverse Reactions
Most common (>= 20%) Pyrexia, rash, hyperkeratosis, headache, arthralgia, papilloma, alopecia, palmar-plantar erythrodysesthesia syndrome, chills, cough, nausea, vomiting, diarrhea, fatigue, dry skin, myalgia, constipation, decreased appetite, edema, hemorrhage, dyspnea, musculoskeletal pain, abdominal pain, epistaxis, dermatitis acneiform
Serious New primary malignancies (cutaneous and non-cutaneous RAS mutation-positive), hemorrhage, cardiomyopathy, uveitis, serious febrile reactions, serious skin toxicities including SCAR, hyperglycemia, glucose-6-phosphate dehydrogenase deficiency, hemophagocytic lymphohistiocytosis
—
Pharmacology
Dabrafenib is a BRAF kinase inhibitor that targets mutated BRAF V600E, V600K, and V600D enzymes, inhibiting cell growth in BRAF V600 mutation-positive tumors.
—
View Full FDA Information
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Tafinlar
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (11/12)
No coverage data available for Drug B.
UnitedHealthcare
Tafinlar
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (4/8) · Qty limit (1/8)
No coverage data available for Drug B.
Humana
Tafinlar
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
No coverage data available for Drug B.
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Tafinlar.
No savings programs available for Drug B.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
TafinlarView full Tafinlar profile
Zelboraf - Vemurafenib tablet, Film CoatedView full Zelboraf - Vemurafenib tablet, Film Coated profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.